Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that it has obtained market approval from the National Medical Products Administration (NMPA) for its triptorelin microspheres. This treatment is designed for prostate cancer patients who require androgen castration therapy.
Innovative Treatment Option for Prostate Cancer Patients
Triptorelin microspheres, an in-house developed long-acting microspheres preparation, is a monthly intramuscular gonadotropin-releasing hormone agonist. This treatment provides androgen castration therapy for patients suffering from prostate cancer. The microspheres offer significant advantages over conventional injectable triptorelin, including a longer onset time and fewer medication instances. These characteristics can reduce the pain and medication burden on patients, thereby improving drug tolerance and accessibility.
Market Competition and Domestic Innovation
Currently, three imported triptorelin long-acting sustained and controlled-release formulations are available in China, including Ipsen’s Diphereline and Ferring’s Decapeptyl, both one-month preparations, and Ipsen’s three-month preparation Diphereline. Joincare’s version of triptorelin stands out as the first home-grown triptorelin to be approved for marketing in China, marking a significant advancement in domestic pharmaceutical innovation and providing an alternative to imported products for patients in need of prostate cancer treatment.-Fineline Info & Tech
